As Uniqure Nv (Call) (QURE) Stock Price Rose, Holder Nantahala Capital Management LLC Has Trimmed Its Holding by $19.60 Million

uniQure N.V. (NASDAQ:QURE) Logo

Nantahala Capital Management Llc decreased its stake in Uniqure Nv (Call) (QURE) by 38.89% based on its latest 2018Q4 regulatory filing with the SEC. Nantahala Capital Management Llc sold 700,000 shares as the company’s stock rose 107.66% with the market. The hedge fund held 1.10 million shares of the major pharmaceuticals company at the end of 2018Q4, valued at $31.70M, down from 1.80 million at the end of the previous reported quarter. Nantahala Capital Management Llc who had been investing in Uniqure Nv (Call) for a number of months, seems to be less bullish one the $2.36B market cap company. The stock decreased 0.31% or $0.2 during the last trading session, reaching $63.35. About 592,006 shares traded or 14.80% up from the average. uniQure N.V. (NASDAQ:QURE) has risen 137.94% since March 17, 2018 and is uptrending. It has outperformed by 133.57% the S&P500.

Nantahala Capital Management Llc, which manages about $614.40 million and $3.25B US Long portfolio, upped its stake in Armstrong Flooring Inc by 273,300 shares to 2.05M shares, valued at $24.27 million in 2018Q4, according to the filing. It also increased its holding in Scientific Games Corp (Call) (NASDAQ:SGMS) by 1.99M shares in the quarter, for a total of 6.97M shares, and has risen its stake in Uniqure Nv (NASDAQ:QURE).

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on April, 29. They expect $-0.65 earnings per share, down 10.17 % or $0.06 from last year’s $-0.59 per share. After $-0.59 actual earnings per share reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 10.17 % negative EPS growth.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Seekingalpha.com which released: “Spark Therapeutics leads healthcare gainers; Achieve Life Sciences and Cronos Group among losers – Seeking Alpha” on February 25, 2019, also Seekingalpha.com with their article: “GE, DHR, SGMO among premarket gainers – Seeking Alpha” published on February 25, 2019, Schaeffersresearch.com published: “Analysts Target Major Upside for Red-Hot Gene Therapy Stocks – Schaeffers Research” on February 25, 2019. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Globenewswire.com and their article: “uniQure Announces 2018 Financial Results and Highlights Recent Company Progress – GlobeNewswire” published on February 28, 2019 as well as Globenewswire.com‘s news article titled: “Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure NV, and WAVE Life Sciences — Discovering Underlying Factors of Influence – GlobeNewswire” with publication date: February 22, 2019.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 7 analysts covering uniQure (NASDAQ:QURE), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. uniQure had 12 analyst reports since September 24, 2018 according to SRatingsIntel. Chardan Capital Markets maintained uniQure N.V. (NASDAQ:QURE) on Monday, February 25 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 24. Wells Fargo maintained uniQure N.V. (NASDAQ:QURE) on Thursday, February 28 with “Buy” rating. FBR Capital maintained uniQure N.V. (NASDAQ:QURE) rating on Friday, November 16. FBR Capital has “Buy” rating and $72 target. H.C. Wainwright maintained uniQure N.V. (NASDAQ:QURE) on Monday, February 25 with “Buy” rating. On Tuesday, February 26 the stock rating was maintained by SunTrust with “Buy”. The firm earned “Buy” rating on Thursday, March 7 by Cantor Fitzgerald. On Monday, March 4 the stock rating was maintained by Chardan Capital Markets with “Buy”. The firm has “Buy” rating by Wells Fargo given on Friday, March 15. The firm earned “Buy” rating on Monday, February 25 by Cantor Fitzgerald.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.